http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018101831-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3158e1a152d4dffda17ff7b0b6e4c3c1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fee1d544c73b996bea9b1e495c683b09
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5154
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55516
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0639
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001162
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00115
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001153
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001186
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001168
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00117
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39541
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0784
filingDate 2017-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e835c576da78796ba47970dacc0806f
publicationDate 2018-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2018101831-A1
titleOfInvention Pharmaceutical composition for use in the treatment of cancer
abstract The present invention relates to an antigen composition comprising at least one mesothelioma cancer cell associated antigen and a pharmaceutically acceptable carrier for use in the treatment of cancer, in particular mesothelioma, wherein dendritic cells are loaded with said antigen composition and wherein said loaded dendritic cells are administered in combination with one or more checkpoint inhibitors, to patients. The present invention also relates to an antigen composition comprising at least two mesothelioma cancer cell associated antigens and a pharmaceutically acceptable carrier. The present invention further relates to an antigen composition comprising at least two mesothelioma cancer cell associated antigens and a pharmaceutically acceptable carrier, for use as a pharmaceutical, in particular for use in the treatment of mesothelioma.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020000899-A1
priorityDate 2016-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014102220-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135565230
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3676
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24749
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226406004
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399254
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399253
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135410875
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394438

Total number of triples: 44.